Spark Therapeutics Recognized as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
August 11 2017 - 7:30AM
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy
company dedicated to challenging the inevitability of genetic
disease, announced today that it has been named one of the
Philadelphia Business Journal’s “Best Places to Work” for 2017, in
the large company category.
“As a pioneering gene therapy company with deep roots in West
Philadelphia, we are proud to be named one of the 2017 ‘Best Places
to Work’ by the Philadelphia Business Journal,” said Jeffrey D.
Marrazzo, chief executive officer of Spark Therapeutics. “With more
than 300 employees, we have doubled our employee count every year
since our founding in 2013, and it is satisfying to see that our
mission continues to inspire employees. The strength and resilience
of the patients and families we aim to serve are what motivates us
to create the path toward a world where no life is limited by
genetic disease.”
The Philadelphia Business Journal selected winners based on
employee responses to an engagement survey conducted by Quantum
Workplace, an independent employee feedback software company. The
“Best Places to Work” survey measures key areas such as work
environment, professional development and embracing change and new
ideas.
To learn more about Spark Therapeutics and current job openings,
visit www.sparktx.com or follow Spark Therapeutics on LinkedIn.
About Spark TherapeuticsSpark Therapeutics, a
fully integrated company, strives to challenge the inevitability of
genetic disease by discovering, developing and delivering gene
therapies that address inherited retinal diseases (IRDs),
neurodegenerative diseases, as well as diseases that can be
addressed by targeting the liver, such as hemophilia. Spark
Therapeutics has ongoing clinical trials investigating gene
therapies in hemophilia A and B. SPK-8011 is in an ongoing,
dose-escalation Phase 1/2 clinical trial as a potential one-time
therapy for hemophilia A. The company retains full global
commercialization rights to the SPK-FVIII program.
SPK-9001, which has received both breakthrough therapy and orphan
product designations by FDA, and access to the PRIority MEdicines
(PRIME) Program by EMA, is in a Phase 1/2 clinical trial for
hemophilia B and is being developed in collaboration with Pfizer.
Our most advanced investigational candidate, with proposed trade
name LUXTURNA™ (voretigene neparvovec), is currently under Priority
Review with FDA for the treatment of biallelic RPE65-mediated IRD
and has been designated as a drug for a rare pediatric disease. The
marketing authorization application for LUXTURNA has been submitted
to EMA for the treatment of vision loss due to Leber congenital
amaurosis or retinitis pigmentosa caused by confirmed biallelic
RPE65 mutations. LUXTURNA has received breakthrough therapy and
orphan product designations from FDA and orphan product
designations from EMA. The pipeline also includes SPK-7001 in an
ongoing Phase 1/2 clinical trial for choroideremia. For more
information on our pipeline, visit www.sparktx.com.
Investor Relations Contact:
Ryan Asay
Ryan.asay@sparktx.com
(215) 239-6424
Media Contact:
Monique da Silva
Monique.dasilva@sparktx.com
(215) 282-7470
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Sep 2023 to Sep 2024